Associate Professor, Internal Medicine, Washington University School of Medicine

Hematology

Michael Tomasson practices Hematology. He received 1 awards: "Elected Member". Michael Tomasson is a published doctor and has 50 publications published. The lastest was: 'Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression.' He accepts Medicare payments and is registered with Medicare.gov.

Publications

---

• A strategy for combating melanoma with oncogenic c-Myc inhibitors and targeted nanotherapy.
• The skinny on obesity and plasma cell Myeloma: a review of the literature.
• Influence of Body Mass Index on Survival in Veterans With Multiple Myeloma.
• Very Late Antigen-4 (?(4)?(1) Integrin) Targeted PET Imaging of Multiple Myeloma.
• The epoxyketone-based proteasome inhibitors carfilzomib and orally bioavailable oprozomib have anti-resorptive and bone-anabolic activity in addition to anti-Myeloma e...
• Clonal evolution in relapsed Acute myeloid leukaemia revealed by whole-genome sequencing.
• Molecular-targeted therapies for hematologic Malignancies.
• Recurrent mutations in the U2AF1 splicing factor in myelodysplastic Syndromes.
• Use of whole-genome sequencing to diagnose a cryptic fusion oncogene.
• Sequencing a mouse Acute promyelocytic leukemia genome reveals genetic events relevant for disease progression.
• DNMT3A mutations in Acute myeloid leukemia.
• CXCR4-mediated bone marrow progenitor cell maintenance and mobilization are modulated by c-kit activity.
• Mcl1 haploinsufficiency protects mice from Myc-induced Acute myeloid leukemia.
• Recurring mutations found by sequencing an Acute myeloid leukemia genome.
• Acquired copy number alterations in adult Acute myeloid leukemia genomes.
• Cancer stem cells: a guide for skeptics.
• Identification of somatic JAK1 mutations in patients with Acute myeloid leukemia.
• Somatic mutations and germline sequence variants in the expressed tyrosine kinase genes of patients with de novo Acute myeloid leukemia.
• The Jak2V617F oncogene associated with myeloproliferative Diseases requires a functional FERM domain for transformation and for expression of the Myc and Pim proto-onc...
• Csf3r mutations in mice confer a strong clonal HSC advantage via activation of Stat5.
• Bortezomib inhibits osteoclast activity in patients with multiple Myeloma.
• Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital Neutropenia.
• Myeloproliferative Disease induced by TEL-PDGFRB displays dynamic range sensitivity to Stat5 gene dosage.
• Neoplasia driven by mutant c-KIT is mediated by intracellular, not plasma membrane, receptor signaling.
• c-Myc rapidly induces Acute myeloid leukemia in mice without evidence of lymphoma-associated antiapoptotic mutations.
• Complete remission of TEL-PDGFRB-induced myeloproliferative Disease in mice by receptor tyrosine kinase inhibitor SU11657.
• Platelet and osteoclast beta3 integrins are critical for bone metastasis.
• A pilot study of high-throughput, sequence-based mutational profiling of primary human Acute myeloid leukemia cell genomes.
• An activated receptor tyrosine kinase, TEL/PDGFbetaR, cooperates with AML1/ETO to induce Acute myeloid leukemia in mice.
• A murine model of CML blast crisis induced by cooperation between BCR/ABL and NUP98/HOXA9.
• Germinal center B-cells resist transformation by kras independently of tumor suppressor arf.
• Neurobeachin (NBEA) is a target of recurrent interstitial deletions at 13q13 in patients with MGUS and multiple Myeloma.
• Bortezomib administered pre-auto-SCT and as maintenance therapy post transplant for multiple Myeloma: a single institution phase II study.
• DNA sequencing of a cytogenetically normal Acute myeloid leukaemia genome.
• The activity and toxicity of low dose clofarabine against relapsed or refractory Myeloma.
• The TEL/PDGFbetaR fusion in chronic myelomonocytic Leukemia signals through STAT5-dependent and STAT5-independent pathways.
• Interleukin 3 and granulocyte-macrophage colony-stimulating factor are not required for induction of chronic myeloid Leukemia-like myeloproliferative disease in mice b...
• Induction of myeloproliferative Disease in mice by tyrosine kinase fusion oncogenes does not require granulocyte-macrophage colony-stimulating factor or interleukin-3.
• Fatal myeloproliferation, induced in mice by TEL/PDGFbetaR expression, depends on PDGFbetaR tyrosines 579/581.
• TEL/PDGFbetaR induces hematologic Malignancies in mice that respond to a specific tyrosine kinase inhibitor.
• Intrinsic human immunodeficiency virus type 1 resistance of hematopoietic stem cells despite coreceptor expression.
• Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative Disease in mice by retrovirally transd...
• The TEL/platelet-derived growth factor beta receptor (PDGF beta R) fusion in chronic myelomonocytic Leukemia is a transforming protein that self-associates and activat...
• The TEL gene and human Leukemia.
• Supraventricular tachyarrhythmias after hematopoietic stem cell transplantation: incidence, risk factors and outcomes.
• Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity.
• Reduced risk of Acute GVHD following mobilization of HLA-identical sibling donors with GM-CSF alone.
• Legal, ethical, and conceptual bottlenecks to the development of useful genomic tests.
• A randomized double-blind trial of hydroxychloroquine for the prevention of Chronic graft-versus-host disease after allogeneic peripheral blood stem cell transplantation.

Schools

---

• Stanford University

• Stanford University Hospital

• Massachusetts General Hospital

Procedures Preformed

---

• HPC Transplantation (Stem Cell Transplant)
• Plasmapheresis
• Thoracentesis

Conditions Treated

---

• Acute Leukemia
• Adrenal Gland Cancer
• Anemia
• Antiphospholipid Syndrome (APS)
• View All

Doctors Specialties

---

• Hematology
• Medical Oncology
• Oncology

Accepted Insurances

---

Awards

---

• Elected Member

Education

---

• Massachusetts General Hospital
• Stanford University

Hospital

---

• Barnes-Jewish Hospital

Helpful Reviews

---

Give Anonymous Review

Medicare Facts

---

National Provider Identifier [NPI]	1841216157
Last Name Of The Provider	TOMASSON
First Name Of The Provider	MICHAEL
View All

Similar Doctors

---

	Dr. Philip W. Majerus, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Craig R. Hildreth, MD This Doctor is OpenDoctor Recommended.
	Dr. Armin Ghobadi, MD This Doctor is OpenDoctor Recommended.
	Dr. Taneemul Haque, MD This Doctor is OpenDoctor Recommended.
	Dr. James M. Epstein, MD
	Dr. Leonard A. White Jr., MD This Doctor is OpenDoctor Recommended.
	Dr. Elaine M. Majerus, MD This Doctor is OpenDoctor Recommended.
	Dr. Charles S. Eby, MD This Doctor is OpenDoctor Recommended. This doctor has more publications
	Dr. Emily S. Popovic, DO This Doctor is OpenDoctor Recommended.
	Dr. Karthik V. Iyer, MD This Doctor is OpenDoctor Recommended.
	Dr. Brenda J. Grossman, MD

---

Doctor Directory | TOS | twitter | FB | Angel | blog